3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Conditions
Melanoma
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, T-Cell
1
Head and Neck Carcinoma
1
Glioblastoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Interventions
pembrolizumab
12
Cisplatin
5
Cetuximab
5
Paclitaxel
4
durvalumab
3
Nivolumab
3
Ipilimumab
3
Gemcitabine
3
Cyclophosphamide
3
poly ICLC
2
avelumab
2
Radiation
2
Pemetrexed
2
Leucovorin
2
Irinotecan
2
Fluorouracil
2
Carboplatin
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
vistusertib
1
tislelizumab
1
tirbanibulin
1
spartalizumab
1
sonidegib
1
sitravatinib
1
repotrectinib
1
pralsetinib
1
pertuzumab
1
pepinemab
1
obinutuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Carcinoma
×
Solutions
×
Clear all
NCT06022757
2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2
Recruiting
204 enrolled